Literature DB >> 29891914

Obstetric and vascular antiphospholipid syndrome: same antibodies but different diseases?

Pier Luigi Meroni1, Maria Orietta Borghi2,3, Claudia Grossi2, Cecilia Beatrice Chighizola2,3, Paolo Durigutto4, Francesco Tedesco2.   

Abstract

Recurrent thrombosis and miscarriages are the main clinical manifestations of antiphospholipid syndrome (APS). Although most patients display both clinical signs, some patients can have isolated vascular or obstetric variants. Emerging data raise the question of whether obstetric and vascular APS are the same or different diseases. An important difference between the two conditions is that a thrombophilic state is a common feature in vascular APS, whereas clot occlusions of the decidual spiral arteries are seldom observed in obstetric APS, and infarctions are found in only one-third of APS placentae. Conversely, inflammation, which is undetectable in vascular APS, is frequently observed in the placentae of patients with obstetric APS and has been documented in the placentae of pregnant mice with fetal loss mediated by antiphospholipid antibodies. Attempts to identify different antibodies or epitopes responsible for the two clinical manifestations of APS have so far been unsuccessful. Possible mechanisms exist that might explain the development of the two clinical presentations, including the tissue distribution and expression level of the main target antigen of antiphospholipid antibodies, β2 glycoprotein I (β2GPI). The identification of the factors that promote the onset of either obstetric or vascular APS has important diagnostic and therapeutic implications.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29891914     DOI: 10.1038/s41584-018-0032-6

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  26 in total

1.  Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.

Authors:  Eva N Hamulyák; Luuk Jj Scheres; Mauritia C Marijnen; Mariëtte Goddijn; Saskia Middeldorp
Journal:  Cochrane Database Syst Rev       Date:  2020-05-02

2.  A high-risk laboratory profile of antiphospholipid antibodies and thrombosis is associated with a large number of extra-criteria manifestations in obstetric antiphospholipid syndrome.

Authors:  Sebastián Udry; José Omar Latino; Cristina Belizna; Silvia Perés Wingeyer; Diego Santiago Fernández Romero; Gabriela de Larrañaga
Journal:  Immunol Res       Date:  2019-12       Impact factor: 2.829

3.  Introduction of Female Reproductive Processes and Reproductive Diseases.

Authors:  Jiajia Zhang; Jiao Li; Jie Yan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Increased Adhesive Potential of Antiphospholipid Syndrome Neutrophils Mediated by β2 Integrin Mac-1.

Authors:  Gautam Sule; William J Kelley; Kelsey Gockman; Srilakshmi Yalavarthi; Andrew P Vreede; Alison L Banka; Paula L Bockenstedt; Omolola Eniola-Adefeso; Jason S Knight
Journal:  Arthritis Rheumatol       Date:  2020-01       Impact factor: 10.995

Review 5.  Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy.

Authors:  Manuel Serrano; Gerard Espinosa; Antonio Serrano; Ricard Cervera
Journal:  Int J Mol Sci       Date:  2022-04-29       Impact factor: 6.208

6.  Long Term Follow up of Patients With Primary Obstetric Antiphospholipid Syndrome.

Authors:  Stanley Niznik; Micha J Rapoport; Orly Avnery; Aharon Lubetsky; Ronen Shavit; Martin H Ellis; Nancy Agmon-Levin
Journal:  Front Pharmacol       Date:  2022-04-21       Impact factor: 5.988

7.  Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study.

Authors:  Hui Jiang; Chu-Han Wang; Nan Jiang; Jing Li; Chan-Yuan Wu; Qian Wang; Meng-Tao Li; Xin-Ping Tian; Jiu-Liang Zhao; Yan Zhao; Xiao-Feng Zeng
Journal:  Arthritis Res Ther       Date:  2021-05-08       Impact factor: 5.156

Review 8.  Reproductive Issues and Pregnancy Implications in Systemic Sclerosis.

Authors:  Maria-Grazia Lazzaroni; Francesca Crisafulli; Liala Moschetti; Paolo Semeraro; Ana-Rita Cunha; Agna Neto; Andrea Lojacono; Francesca Ramazzotto; Cristina Zanardini; Sonia Zatti; Paolo Airò; Angela Tincani; Franco Franceschini; Laura Andreoli
Journal:  Clin Rev Allergy Immunol       Date:  2022-01-18       Impact factor: 8.667

Review 9.  Effects of anti-beta 2-glycoprotein 1 antibodies and its association with pregnancy-related morbidity in antiphospholipid syndrome.

Authors:  Juan J Fierro; Manuela Velásquez; Angela P Cadavid; Karina de Leeuw
Journal:  Am J Reprod Immunol       Date:  2021-12-04       Impact factor: 3.777

10.  Antiphospholipid Antibodies Increase Endometrial Stromal Cell Decidualization, Senescence, and Inflammation via Toll-like Receptor 4, Reactive Oxygen Species, and p38 MAPK Signaling.

Authors:  Mancy Tong; Teimur Kayani; Deidre M Jones; Jane E Salmon; Shannon Whirledge; Lawrence W Chamley; Vikki M Abrahams
Journal:  Arthritis Rheumatol       Date:  2022-04-27       Impact factor: 15.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.